Eximore Series A

Eximore Ltd is a biopharmaceutical company focused on the development, and commercialization of our innovative proprietary "pack and release" punctal plug technology therapy for diseases of the eye. Eximore is positioned to become a central player in the ophthalmic space due to our ability to create drug delivery solutions that reduce the complexity and burden of the current eye drops standard of care by developing a non-invasive, sustained-release alternative. With a focus on advancing our Glaucoma and Dry Eye products through to Phase 2 clinical trials, our goal is to overcome the issues of patient adherence and compliance by providing means of more consistent and reliable drug dosing for better patient outcomes.